Roche and Foundation Medicine rebranded Saga Diagnostics’ minimal residual disease test after Roche’s $595 million acquisition earlier this year, renaming Pathlight MRD to FoundationOne MRD and signaling plans to broaden indications beyond the breast cancer use case. The patient-specific approach uses whole-genome sequencing and a structural-variant “fingerprint,” followed by digital PCR on circulating tumor DNA to generate MRD results. Foundation Medicine’s chief medical officer Todd Druley said the platform’s structural-variant focus is designed to improve sensitivity and reduce false calls linked to sequencing errors and to shifting mutation profiles during disease evolution. The company also positioned the assay as faster and potentially cheaper than fully sequencing-based MRD workflows, aiming to support scalable adoption in routine labs.